Cargando…

Commentary: Is Torasemide a Potential Agent in the Treatment of Autism?

Detalles Bibliográficos
Autores principales:	Machado, Sergio, Lucas Lima, João, Imperatori, Claudio, Souza de Sá Filho, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AVES 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985063/ https://www.ncbi.nlm.nih.gov/pubmed/36879994 http://dx.doi.org/10.5152/alphapsychiatry.2023.27122022

Ejemplares similares

Neuropsychiatric Consequences of COVID-19: What Do We Know So Far?
por: Machado, Sergio, et al.
Publicado: (2022)

Subjective Cognitive Decline and Quality of Life During Aging: A Thin Line Between Healthy and Pathological?
por: Machado, Sergio, et al.
Publicado: (2023)

Torasemide Improves the Propionic Acid-Induced Autism in Rats: A Histopathological and Imaging Study
por: Doğan, Murat, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats
por: Roche‐Catholy, Marine, et al.
Publicado: (2022)

Health-Related Fitness as a Predictor of Anxiety Levels Among School Adolescents: An observational cross-sectional study
por: Legey, Sandro, et al.
Publicado: (2022)

Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)
por: McCallum, Linsay, et al.
Publicado: (2020)

Safety of torasemide in healthy adult dogs administered daily for 26 weeks
por: Coussanes, Evelyne, et al.
Publicado: (2021)

The Diuretic Torasemide Does Not Prevent Aldosterone-Mediated Mineralocorticoid Receptor Activation in Cardiomyocytes
por: Gravez, Basile, et al.
Publicado: (2013)

Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure
por: Ballester, Maria Rosa, et al.
Publicado: (2015)

Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs
por: Pelligand, Ludovic, et al.
Publicado: (2020)

Tolerance of torasemide in cats with congestive heart failure: a retrospective study on 21 cases (2016–2019)
por: Poissonnier, Camille, et al.
Publicado: (2020)

Short‐Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study
por: Chetboul, V., et al.
Publicado: (2017)

Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study
por: Besche, Beatrice, et al.
Publicado: (2020)

Comparative effectiveness of furosemide vs torasemide in symptomatic therapy in heart failure patients: A randomized controlled study protocol
por: Li, Yifan, et al.
Publicado: (2021)

Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry()
por: Zhang, Lin, et al.
Publicado: (2016)

Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trial
por: Balsam, Paweł, et al.
Publicado: (2020)

The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure – TORNADO: a study protocol for a randomized controlled trial
por: Balsam, Paweł, et al.
Publicado: (2017)

Effect of photodynamic therapy combined with torasemide on the expression of matrix metalloproteinase 2 and sodium-potassium-chloride cotransporter 1 in rat peritumoral edema and glioma
por: LI, BO, et al.
Publicado: (2016)

Efficacy of metoprolol combined with torasemide in elderly patients with degenerative valvular heart disease and heart failure and its influence on NT-proBNP levels
por: Ren, Kai, et al.
Publicado: (2023)

The expanding CML treatment landscape: an introspective commentary
por: Lipton, Jeffrey H.
Publicado: (2023)

Commentary – Exosomes: Realization of the great therapeutic potential of stem cells
por: Volpe, J.J.
Publicado: (2020)

Therapeutic Potential of Natural Pharmacological Agents in the Treatment of Human Diseases
por: Ramana, Kota V., et al.
Publicado: (2014)

COVID-19 and Quarantine: Expanding Understanding of How to Stay Physically Active at Home
por: Sá Filho, Alberto Souza, et al.
Publicado: (2020)

Vaccination and Vaccine Effectiveness: A Commentary of Special Issue Editors
por: Costantino, Claudio, et al.
Publicado: (2020)

The epistemic challenges of CTOs: Commentary on . . . Community treatment orders†
por: Light, Edwina
Publicado: (2014)

Commentary on “Emerging Technologies in the Treatment of Adult Spinal Deformity”
por: Hyun, Seung-Jae
Publicado: (2021)

Vagal Nerve Stimulation for the Treatment of Autism
por: Derakhshan, Nima
Publicado: (2015)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2021)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2021)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2021)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2022)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2020)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2021)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2022)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2022)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2022)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2023)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2023)

Editorial Commentary
por: Jirge, Padma Rekha
Publicado: (2023)

Commentary on “The Role of Alginate Hydrogels as a Potential Treatment Modality for Spinal Cord Injury: A Comprehensive Review of the Literature”
por: Kumar, Hemant
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ttcqmbu3u54b86krdp7nhup8je